Clinical Trials
CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China
CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for BI-1206, a First-in-class fully...
Clinical Trials
Clovers COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial
Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that an investigator-led, Phase 2 trial initiated to evaluate the immunogenicity and safety of heterologous and homologous COVID-19 booster vaccines. Clover’s COVID-19 vaccine...
Clinical Trials
Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19
Emmes announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus...
Clinical Trials
Ascelia Pharma presents study showing comparable efficacy of Orviglance lesion visualization and detection to Gadolinium
Ascelia Pharma AB is presenting a study in which Orviglance® (manganese chloride tetrahydrate, former working name Mangoral) was compared against a gadolinium-based contrast agent at one of the world’s largest radiology conference, RSNA, in Chicago, Illinois.
Orviglance is a novel...
Clinical Trials
Single Dose of Regen-Cov Provides Long-Term Protection Against COVID-19
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1
During the 8-month assessment period there were 0 hospitalizations...
Clinical Trials
Ferrer announces first patient enrollment of FNP122 in ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis treatment
Ferrer, an international pharmaceutical company focused on neurological disorders and pulmonary vascular and interstitial lung diseases, has announced the next major milestone in its mission to develop transformative therapies for Amyotrophic Lateral Sclerosis (ALS) – marked by the first...
Clinical Trials
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration
Antios Therapeutics, Inc. and Assembly Biosciences, Inc. announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read